References
- San Miguel JF, Almeida J, Mateo G, Bladé J, López-Berges C, Caballero D, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853–6.
- Szea DM, Brown RD, Yang S, Gibson J, Ho J, Fazekas de St Groth B, et al. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leuk Lymphoma 2003;44:1557–68.
- Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 1996;87:1196–8.
- Allegra A, Alonci A, Penna G, Russo S, Gerace D, Greve B, et al. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: A case report and a review of treatment options. Hematol Oncol 2012;30:41–5.
- Penna G , Allegra A, Romeo G, Alonci A, Cannavò A, Russo S, et al. Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncol 2012;51:944–7.
- Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci U S A 1971;68:3130–5.
- Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990;145:1029–36.
- King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998;4:1281–6.
- Holm G, Bergenbrant S, Lefvert AK, Yi Q, Osterborg A, Mellstedt H. Anti-idiotypic immunity as a potential regulator in myeloma and related diseases. Ann N Y Acad Sci 1991;636:178–83.
- Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995;86:3043–9.
- Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, et al. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209–15.
- Morel E, Escamochero S, Cabañas R, Díaz R, Fiandor A, Bellón T. D94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol 2010;125:703–10.
- Yi Q. Novel immunotherapies. Cancer J 2009;15:502–10.
- Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immunity 2003;3:9–13.
- Moore A, Medarova Z, Potthast A, Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004;64:1821–7.
- Lim SH, Chiriva-Internati M, Wang Z, Salati E. Sperm protein 17 (Sp17) as a tumor vaccine for multiple myeloma. Blood 2002;100:673a.
- Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 2002;100:961–5.